Federica Mori

Title: Federica Mori: Innovator in Cancer Vaccine Development

Introduction

Federica Mori is a prominent inventor based in Rome, Italy. She has made significant contributions to the field of biotechnology, particularly in the development of vaccines for cancer treatment. With a total of 2 patents, her work focuses on innovative approaches to combat tumors and cancers.

Latest Patents

Mori's latest patents include a groundbreaking Matrix metalloproteinase 11 vaccine. This invention involves compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3), or the nucleic acid encoding MMP-11 for use in vaccines targeting tumors that overexpress MMP-11. The compositions are designed to enhance the immune response against cancer cells. In particular embodiments, the compositions include a nucleic acid encoding a fusion polypeptide that features catalytically inactivated MMP-11 linked to an immunoenhancing element. The codons for both the MMP-11 and the immunoenhancing element have been optimized for improved expression in human cells. These compositions can be utilized alone or in combination with other vaccines and conventional therapies, such as radiation and chemotherapy.

Career Highlights

Throughout her career, Federica Mori has worked with esteemed organizations, including the Instituto di Ricerche di Biologia Molecolare P. Angeletti. Her research has been pivotal in advancing the understanding of cancer immunotherapy and developing effective treatment options.

Collaborations

Mori has collaborated with notable colleagues, including Luigi Aurisicchio and Daniela Peruzzi. These partnerships have fostered a collaborative environment that enhances the innovation process in her research endeavors.

Conclusion

Federica Mori's contributions to cancer vaccine development exemplify her dedication to advancing medical science. Her innovative patents and collaborative efforts position her as a key figure in the fight against cancer.